Overview

• Life science tools firm's Q4 revenue decreased 1% but beat analyst expectations

• Adjusted EPS for Q4 met analyst expectations

• Company is implementing Revival program, including VWR brand relaunch and e-commerce upgrades

Outlook

• Company is focusing on top-line growth and strategic investments in 2026

• Avantor aims to create sustainable shareholder value through strategic initiatives

• Revival program includes relaunch of VWR brand and e-commerce upgrades

Result Drivers

• REVIVAL PROGRAM - Avantor is executing a Revival program to improve agility and customer focus, including VWR brand relaunch and e-commerce upgrades

• FOREIGN CURRENCY IMPACT - Foreign currency translation positively impacted sales, offsetting some of the organic decline

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 15 "hold" and 2 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for Avantor Inc is $12.05, about 8% above its February 10 closing price of $11.16

• The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release: ID:nPn1Mz9V5a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.